Photo from wikipedia
While left ventricular assist devices (LVAD) successfully unload the failing ventricle, most hearts do not regain sufficient function to allow for device explantation. Herein, we report a pilot series of… Click to show full abstract
While left ventricular assist devices (LVAD) successfully unload the failing ventricle, most hearts do not regain sufficient function to allow for device explantation. Herein, we report a pilot series of LVAD patients treated with interleukin-1 receptor antagonism as a biologic adjuvant that safely and effectively treated inflammation so as to create a milieu whereby the heart could functionally improve. This pilot study sets the stage for a more rigorous, controlled trial of interleukin-1 receptor antagonism in treating heart failure and promoting myocardial recovery in patients supported by LVADs.
Journal Title: ASAIO Journal
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!